RAC — Race Oncology Income Statement
0.000.00%
Last trade - 00:00- AU$738.41m
- AU$724.75m
- AU$0.79m
- 59
- 10
- 86
- 52
Annual income statement for Race Oncology, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.019 | 0.054 | 0.592 | 0.833 | 0.788 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 6.36 | 11.3 | 10.5 | 14.7 | 5.58 |
| Operating Profit | -6.34 | -11.2 | -9.92 | -13.8 | -4.79 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.34 | -11.2 | -9.92 | -13.8 | -4.79 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.34 | -11.2 | -9.92 | -13.8 | -4.79 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.34 | -11.2 | -9.92 | -13.8 | -4.79 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.34 | -11.2 | -9.92 | -13.8 | -4.79 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.048 | -0.073 | -0.061 | -0.083 | -0.027 |